Karl Christian Heller
Algemeen Directeur bij Freeline Therapeutics GmbH
Profiel
Karl Christian Heller currently works in Freeline Therapeutics GmbH as a Co-Managing Director.
Actieve functies van Karl Christian Heller
Bedrijven | Functie | Begin |
---|---|---|
Freeline Therapeutics GmbH
Freeline Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Ascend Gene & Cell Therapies Ltd., Freeline Therapeutics GmbH is a German biotechnology company that focuses on liver directed gene therapies for bleeding disorders and other chronic diseases. The company is based in Planegg, Germany. The company has a pipeline of gene therapies that have the potential to change the lives of people with chronic, debilitating diseases. Freeline has two key enabling platforms critical to realizing AAV gene therapy across its indications\: its proprietary AAV vector platform and its high-performing manufacturing platform. The company was founded in 2015, and the CEOs are Markus Hörer and Karl Christian Heller. Freeline Therapeutics was acquired by Ascend Gene & Cell Therapies Ltd. from Freeline Therapeutics Holdings Plc on February 10, 2023 for $25.83 million. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Freeline Therapeutics GmbH
Freeline Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Ascend Gene & Cell Therapies Ltd., Freeline Therapeutics GmbH is a German biotechnology company that focuses on liver directed gene therapies for bleeding disorders and other chronic diseases. The company is based in Planegg, Germany. The company has a pipeline of gene therapies that have the potential to change the lives of people with chronic, debilitating diseases. Freeline has two key enabling platforms critical to realizing AAV gene therapy across its indications\: its proprietary AAV vector platform and its high-performing manufacturing platform. The company was founded in 2015, and the CEOs are Markus Hörer and Karl Christian Heller. Freeline Therapeutics was acquired by Ascend Gene & Cell Therapies Ltd. from Freeline Therapeutics Holdings Plc on February 10, 2023 for $25.83 million. | Commercial Services |